The pulmonary drugs market is estimated to be valued at US$ 3.41 Bn or US$ billion in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Pulmonary drugs are used for the treatment of various respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, pulmonary fibrosis and other respiratory diseases. These drugs are administered through various routes such as inhalation, intravenous and oral. Some of the common classes of pulmonary drugs include bronchodilators, anti-inflammatory drugs, monoclonal antibodies, antihistamines and others. These drugs helps in widening the airways, reducing inflammation and mucus production, and treats other symptoms associated with respiratory diseases.

Market Dynamics:
Growing prevalence of respiratory diseases such as asthma and COPD is a major factor driving the growth of the pulmonary drugs market. According to WHO, around 235 million people suffer from asthma globally and around 251 million people suffer from COPD. In addition, factors such as increasing pollution levels, rising cigarette smoking and growing geriatric population are also fueling the burden of respiratory diseases worldwide. This is expected to increase the demand for pulmonary drugs for treatment over the forecast period. Furthermore, advancing drug development and approval with novel mechanism of action is also expected to boost the market growth. For instance, in 2019, FDA approved Dupixent (dupilumab), an interleukin-4 receptor alpha antagonist, for treatment of asthma.

Segment Analysis
The pulmonary drugs market is dominated by the anti-asthmatics and COPD sub-segment. This is because asthma and COPD have high prevalence rates across regions and require continuous treatment. Anti-asthmatics control asthma symptoms and exacerbations while drugs for COPD help dilate airways and make breathing easier.

PEST Analysis
Political: Government support in the form of favorable regulations for drug research, approval and availability have boosted market growth. Various organizations create awareness about respiratory diseases.
Economic: Rising healthcare spending, growing middle class in emerging nations and increasing disposable incomes have augmented demand.
Social: Changing lifestyles, increasing pollution levels, growing tobacco consumption and aging population are key factors driving disease burden.
Technological: Advancements in drug delivery systems, development of combination therapies and focus on specialty medicines have widened treatment options.

Key Takeaways
Global Pulmonary Drugs Market Size is expected to witness high growth, exhibiting CAGR of 8.1% over the forecast period, due to increasing respiratory disease prevalence globally. According to WHO, COPD affected over 384 million people in 2020 and was the third leading cause of death. The market size for 2023 is estimated to be US$ 3.41 Bn.

The North America pulmonary drugs market holds the largest share due to developed healthcare infrastructure, higher disease awareness and significant research focus. However, Asia Pacific is expected to grow at fastest pace owing to large patient pool, improving access to diagnosis and treatment and rising pollution levels.

Key players operating in the pulmonary drugs market include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited. These players are focused on launching advanced features drugs having minimal side effects. 

Read More- https://www.newsstatix.com/pulmonary-drugs-market-value-insights-and-forecast/